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Introduction  
Bronchial asthma is a disease of continuing 
inflammatory disorder of the airways that causes 
trouble breathing1. It is a major cause of chronic 
morbidity and mortality throughout the world and 
there is evidence that its prevalence has increased 
considerably over the past 20 years especially in 
children .The prevalence of asthma symptoms in 
children varies from 1 to more than 30% in 
different populations and is increasing in most 
countries 2. 
In Egypt, asthma is the commonest cause of 
emergency and hospital admission where the 
prevalence among children aged 3-15 years 
estimated to be 8.2%, with 10% annual increase in 
mortality 3. 
The genetics of asthma is important in pediatric 
asthma. Current clinical Knowledge of genetic 
aspects of asthma is needed to understand the 
epidemiology, pathogenesis, natural history and 
management of children with asthma 4. 
Identifying the genes associated with asthma 
offers a means of better define of its pathogenesis, 
with the promise of improving preventive 
strategies, diagnostic tools and therapies 5. 
  
Human genetics and etiology of asthma 
The genetic contribution to asthma is large. 
Twin studies have indicated a considerable genetic 
component and also have shown that individual 
environmental factors are important 6. 
There is a growing list of asthma susceptibility 
genes but limited data as yet on how or to what 
extent they determine the clinical presentation of 
asthma7. However, several locations have been 
linked to asthma and atopy8. 
A major consideration for positional cloning of 
asthma genes is to determine the specific marker, or 
phenotype, that will be used to identify asthma. 
Examples can include immunoglobulin (IgE) levels, 
doctor-diagnosed asthma, or airway hyper-
responsiveness. It is important to consider that 
although the various asthma markers are 
correlative, they are not the same, and the 
phenotype selection can affect the specific genes 
that are identified. At least 3 "asthma genes" have 
been identified: DPP10, PHF11, and ADAM3.9,10 
DPP10 is a dipeptidyl peptidase, with known 
functions include cleaving the terminal sequences 
from cytokines and chemokines; PHF11 is a 
transcription factor; and ADAM33 is a disintegrin 
and metalloprotease that appears to have a role in 
cell migration, adhesion, and cell-cell interactions. 
The identification of these genes has led to 
intensive research efforts to determine how they 
modify the risk of asthma. It is hoped that the 
insights gained from these studies will lead to new 
therapeutic targets for asthma.9,10 
Many regions of the genome have been found 
to have linkage with the phenotypes of asthma and 
atopy. Over 70 variants in candidate genes have 
been reported to be associated with these 
phenotypes. The main regions of these variants 
have been found on chromosomes 2q, 5q, 6p, 11q, 
12q, 16q and 17q. Five potential asthma 
susceptibility genes or complexes have been 
identified using a positional approach. These are 
ADAM33, DPP10, PHF11 and SETDB2, GPRA 
and SPINK5. It is evident that environmental 
factors will influence the expression of genes and 




It is apparent that investigation of gene-
environment interactions will be very important in 





There is evidence that gene-environment 
interactions play an especially important role in 
diseases, such as asthma, that have a great deal of 
variability in their clinical expression. 
Environmental factors can modify the clinical 
expression of genetic variability in a variety of 




either increase, reduce, or have no effect on the 
clinical expression of asthma13.  
As an example, a collaborative study with a 
German group cited that genes may regulate the 
protective effects of a rural lifestyle on allergies and 
asthma.6 
Previous work by this group had revealed a 
strong relationship between exposure to endotoxin 
and protection from asthma, strongly suggesting 
that innate immune responses were responsible for 
this protection. The research team identified a 
polymorphism of Toll-like receptor 2 (TLR2), 
which is a receptor for bacterial products, including 
endotoxin and peptidoglycan. The study compared 
asthma and allergic markers, such as serum IgE 
levels, between farming and non-farming families. 
A specific polymorphism of TLR2 was associated 
with protection from asthma among children in 
farming families, with high exposure to microbial 
products, but not among families living in relatively 
"clean" urban and suburban homes.12 
The influence of environmental factors, 
including pets, endotoxin, viruses, smoke, and 
pharmacological agents, on the expression of genes 
and the ultimate clinical phenotype is being 
investigated. It appears that they influence the 
immune development in a genotype and as a result, 
modulate the development of asthma and atopy. 
Exposure to dogs in infancy is associated with 
higher IL10 and IL13 cytokine secretion profiles 
and reduced allergic sensitization and atopic 
dermatitis14. 
Vercelli further discussed the conflicting results 
reported regarding CD14 polymorphisms, atopy, 
and exposure to endotoxin. She suggested that there 
would be no association between genotypes and 
atopy with low levels of endotoxin exposure, but 
that the 159T allele would be protective among 
children with moderate exposure.15 
Colilla et al.16 reported evidences of a gene-
environmental interaction in a linkage study of 
asthma and smoking exposure. Also, virus exposure 
appears to be related to the development of asthma 
in children.17 
In addition, Hull et al.18 suggested that variants 
in IL8 or IL13 may be involved in the development 
of bronchitis or asthma.  
Drug exposure interactions with genes such as 
the β-2 agonists and leukotriens inhibitors appear to 
influence the clinical phenotype of asthma.19,20,21 
 
Genome wide linkage analysis for asthma and 
atopy and related phenotypes 
A review in December 2002 reported that there 
were 12 genome screens for asthma and atopy 
related traits studied and the authors noted at least 
18 regions of the genome having linkage.22 
The replicated regions reported for the asthma 
phenotype have been on 1p, 2q, 4q, 5q, 6p, 12q, 
13q, 14q, 19q, and 21q; For total serum IgE sites on 
2q, 3q, 5q, 6p, 7q, and 12q; Atopy on chromosomes 
3q, 4q, 6p, 11q, and 17q and blood eosinophils 
counts on 15q.21 
 
Candidate genes for asthma and atopy and 
related phenotypes 
Genome-wide linkage analysis (positional) or 
biological factors influencing the asthma 
phenotypes (functional) is the basis used for the 
selection of candidate genes studied for this 
association. The investigations of the most common 
candidate gene variants by chromosomal regions 
will be reviewed 11. 
• Chromosome 2q Region: 
The chromosome 2q region identified in genome 
screens to be linked with the asthma phenotype 
contains the IL1 receptor antagonist (IL1RN) and 
the cytotoxic T lymphocyte antigen-4 (CTLA4) 
genes. Confirmation of variants in IL1RN being 
associated with asthma and allergy has been 
reported 23-24. 
Van Oosterhout et al.25 noted that CTLA4 is 
expressed only in activated T cells and is a 
powerful negative regulator of T cell activation. 
While Yang et al.26 reported that a polymorphism in 
CTLA4 is associated with elevated serum levels of 
total IgE and allergic rhinitis in females. 
Single nucleotide polymorphisms (SNPs) in 
CTLA4 have been reported to be associated with 
asthma, serum IgE, asthma severity, and airway 
responsiveness19. Moreover, Bourgain et al.27 
recently reported a P-selectin as an atopy 
susceptibility locus. 
• Chromosome 5q and 16q Regions 
It has been well demonstrated that activation of the 
IL4 receptor gene (IL4RA) stimulates the 
production of total serum IgE. IL4 receptor gene is 
located on chromosome 5q31 and IL4RA on 
chromosome 16p12, both of which are found on 
genomic regions linked to the asthma phenotype.19 
Recently, Beghe et al.28 noted that a 
polymorphism in the IL4 and IL4RA chain genes 
confers susceptibility to asthma and atopy in a 
Caucasian population. 
Other genes on chromosome 5, including those 
for IL13 (IL13), monocyte differentiation antigen 
CD14 (CD14), serine protease inhibitor kazal type 
5 (SPINK5), and leukotrien C4 synthase .19 
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• Chromosome 6p21 Region 
Human leukocyte antigen (HLA) DRB1 (HLA-
DRB1), TNF α, and lymphotoxin- α ( LTA ) have 
been reported to be associated with asthma 
phenotypes ;For years, it has been known that HLA 
class II molecules are involved in controlling the 
immune response to allergens.29 
Functional SNPs or haplotypes in HLA-DRB1 
have been reported in association with allergic 
specific IgE responses11.  
Recently, Moffatt et al.30 noted a relationship of 
atopy, respiratory function, and HLA-DR in 
aboriginal Australians. Also, a functional variant of 
TNFA-308 is associated with asthma. Moreover, 
The observation of a functional variant in the 
promoter of TNFA  was associated with asthma and 
high serum IgE levels.31,32  
• Chromosome 11q13 Region 
The gene for the beta chain of the high affinity 
receptor for IgE on chromosome 11q13, a genome 
region linked to atopy, has been reported. SNPs or 
haplotypes in FCERIB have been associated with 
asthma and their associated phenotypes19,29. No 
recent studies have been conducted on this area.  
• Chromosome 12q Region 
SNPs and haplotypes for the signal transducer and 
activator of transcription 6 gene (STAT6) and the 
nitric oxide synthase 1 gene (NOS1) have been well 
described to be associated with asthma and atopy.19 
STAT6 has been reported by Nagarkatti et al .33 
to be involved in the initiation of signals from Th2 
cells, particularly through IL4 and IL13 receptors in 
an Indian population. They and others have 
reported that variants of STAT6 are associated with 
asthma, allergic diseases and total serum 
IgE.19,34,35,36  
Studies have been reported that SNPs in NOS1 
are associated with asthma, eosinophil counts and 
total serum IgE levels19 .Also, it was confirmed that 
SNPs in NOS1 are associated with IgE-mediated 
allergy in a Central European population.37  
• Chromosome 17q Region 
The predominant eosinophil chemo-attractant on 
chromosome 17q is the gene for eotaxin (SCYA11), 
which is involved in allergic inflammation. SNPs in 
its promoter region have been found in many 
studies to be associated with asthma, eosinophil 
count, and lung function.19 Shin's group38 confirmed 
its association with asthma and serum total IgE.  
In addition, many other asthma and atopy 
susceptibility genes have been suggested in the 
literature. These have included those for colony-
stimulating factor 2 (CSF2), IL12B (IL12B), and 
glutathione-S-transferase P1 (GSTP1), all of which 
are located on chromosome 5q. A polymorphism of 
the GMM-CSF gene and the development of atopic 
disease have been reported. 39 
Moreover, Khoo et al.40 reported an association 
of the IL12B promoter polymorphism with reduced 
pulmonary functions in girls. In addition, Lyon et 
al.41 reported that an IL10 gene polymorphism was 
associated with an asthma phenotype in children. 
 
Pharmacogenetic and pharmacogenomic 
approach to asthma treatment  
Pharmacogenomics is the study of the relationship 
between patterns of genetic variability, or 
polymorphism, in sets of genes and individual 
variability in the response of pharmacotherapy. An 
estimated70% to 80%of variability in the individual 
responses to therapy may have genetic basis.42 
Although genes coding for some key treatment 
targets contain little polymorphic variation, like the 
muscarinic M2 and M3 receptors ,other genes 
whose products are important targets of asthma 
treatment contain extensive genetic variation. The 
best example of the later are the beta (2)-
adrenoceptors and 5-lipooxygenase (ALOX5) 
genes.43 Polymorphism of the beta (2)-
adrenoceptors may influence airway responses to 
regular inhaled beta-agonist treatment.44,45 
Treatment with anti-leukotriene drugs results in 
clinical improvement in many though, not all 
patients of asthma. Polymorphism of two genes in 
the leukotriene pathway; the gene and the synthase 
gene, have been demonstrated to have 
pharmacogenetic associations with asthma. 
Polymorphisms of the (ALOX5) promoter genes 
and the leukotriene C4 synthase gene have been 
associated with variation in responses to leukotriene 
modifier therapy.46,47 
Children with asthma having a genetic variant 
that impairs their ability to express ALOX5 have 
more severe disease than those bearing genotypes 
that have more efficient baseline expression of 
ALOX546. 
Corticosteroids are the most potent anti-
inflammatory agents used to treat chronic 
inflammatory diseases, such as asthma. About 5% 
of asthma patients do not respond well or at all to 
corticosteroids therapy. Although this phenomenon 
is uncommon, it posses a difficult therapeutic 
problem.48 
Asthma treatment with inhaled corticosteroids 
demonstrates significant person-to-person 
variability .Genetic variation could contribute to 
these variable responses. One gene, corticotrophin-
releasing hormone receptor 1, demonstrated 




The future of asthma genetic studies 
Asthma genetics researches are still in early stages 
and face some technical problems. Such studies 
require the identification of standardized definitions 
of asthma phenotypes, intermediate biologic 
measures associated with the risk of asthma, well-
defined populations in unbiased studies with 
sufficient power to detect small effects, and the 
methods to concurrently measure both 
environmental and genetic risk factors4. 
Such association studies and biologically 
informative pharmacogenomic trials over the next 
decade should allow us to minimize drug side 
effects and also maximize drug efficacy42. 
Pharmacogenomic assays will be readily 
available in clinical laboratories by 2010. By 
widening the number of potential drug targets and 
better identifying those children, a specific drug is 
likely to benefit and another is likely to harm4. 
 
Conclusion 
In view of the complexity of asthma and atopy, it is 
not clear how many genes and environmental 
factors are involved. The genome screens suggest 
that there may be many genes with moderate 
effects. Most likely, many of these genes that 
influence immunity will prove to be polymorphic. 
As a result, almost any immune response gene may 
be found to have an effect on any immune-mediated 
disease. To determine the clinical relevance of these 
polymorphisms, they should be tested in case-
control studies involving patients with different 
manifestations and severity of the disease.11 
The study of genetic variation with the mapping 
and sequencing of the human genome will have 
major implications in our understanding of 
variability in pathogenetic pathways and response 
to treatment. It is now important to define the 
biological consequences of the small variations in 
genetic sequences known as single nucleotide 
polymorphisms. This is becoming a major driving 
force for understanding the basis for genetic 
variation and disease states such as asthma. This 
concept of pharmacogenetics and pharmaco-
genomics in relation to identification of genetic 
variance in response to drug therapy will have a 









1. Slats AM, Janssen K, Schadewijk A, Plas 
D, Schot R, Aardweg J, et al. Bronchial 
Inflammation and Airway Responses to Deep Inspiration 
in Asthma and Chronic Obstructive Pulmonary Disease. 
American Journal of Respiratory and Critical Care 
Medicine 2007; 176: 121-8. 
2. El-Seify MY. Childhood bronchial asthma: acute 
exacerbation diagnosis and treatment. Egypt J Pediatr 
Allergy Immunol 2007; 5(2):75-6. 
3. Tageldin MA, Aly GS, Mostafa S, Khalil 
H. Epidemiological study of risk factors in pediatric 
asthma. Egypt J Pediatr Allergy Immunol 2007; 5(1):11-9. 
4. Meurer JR, Lustig JM, Jacob HJ. Genetic 
Aspects of the Etiology and Treatment of Asthma. Pediatr 
Clin N Am 2006; 53:715-25. 
5. Cookson WO. Asthma Genetics Chest 2002; 
121(Suppl.) 7S-13S. 
6. Koppelman GH, Los H, Postma DS. Genetic 
and environment in asthma: the answer of twin studies. 
Eur Respir J 1999; 13(1):8-14. 
7. Cookson WO, Moffat M. Making Sense of 
Asthma Genes. N Engl J Med 2004; 315(17):1794-6. 
8. Asher MI, Grant C. Epidemiology of Asthma. In: 
Kendig's Disorders of the respiratory tract in Children. 
Chernick V, Boot TF, Wilmott R, Bush A (Edits). 
Elsevier, USA, 2006; 7th edition: 762-85. 
9. Allen M, Heinzmann A, Noguchi E, et al. 
Positional cloning of a novel gene influencing asthma 
from chromosome 2q14. Nat Genet 2003; 35:258-63. 
10. Van Eerdewegh P, Little RD, Dupuis J, et 
al. Association of the ADAM33 gene with asthma and 
bronchial hyper-responsiveness. Nature 2002; 418:426-30. 
11. Blumenthal MN. The Role of Genetics in the 
Development of Asthma and Atopy. Curr Opin Allergy 
Clin Immunol 2005; 5(2):141-5. 
12. Eder W, Klimecki W, Yu L, et al. Toll-like 
receptor 2 as a major gene for asthma in children of 
European farmers. J Allergy Clin Immunol 2004; 113:482-
8. 
13. Martinez FD. Advances in genetics of allergy and 
asthma: part 1. Gene-environment interactions. Program 
and abstracts of the American Academy of Allergy, 
Asthma & Immunology 60th Annual Meeting; March 19-
23, 2004; San Francisco, California. 
14. Gern JE, Reardon CL, Hoffjan S, et al.  
Effects of dog ownership and genotype on immune 
development and atopy in infancy. J Allergy Clin 
Immunol 2004; 113:307-14. 
Genetic aspects of pediatric asthma 
49 
15. Vercelli D. Learning from discrepancies: CD14 
polymorphisms, atopy and the endotoxin switch. Clin Exp 
Allergy 2003; 33:153-5. 
16. Colilla S, Nicolae D, Pluzhnikov A, et 
al. Evidence for gene-environment interactions in a 
linkage study of asthma and smoking exposure. J Allergy 
Clin Immunol 2003; 111:840-6. 
17. Murray CS, Simpson A, Custovic A. 
Allergens, viruses, and asthma exacerbations. Proc Am 
Thorac Soc 2004; 1:99-104. 
18. Hull J, Rowlands K, Lockhart E, et al. 
Haplotype mapping of the bronchiolitis susceptibility 
locus near IL8. Hum Genet 2004; 114:272-9. 
19. Hoffjan S, Nicolae D, Ober C. Association 
studies for asthma and atopic diseases: a comprehensive 
review of the literature. Respir Res 2003; 4:14. 
20. Sayers I, Barton S, Rorke S, et al. Allelic 
association and functional studies of promoter 
polymorphism in the leukotriene C4 synthase gene 
(LTC4S) in asthma. Thorax 2003; 58:417-24. 
21. Binaei S, Christensen M, Murphy C, et al. 
Beta2-adrenergic receptor polymorphisms in children with 
status asthmaticus. Chest 2003; 123:375S . 
22. Hoffjan S, Ober C. Present status on the genetic 
studies of asthma. Curr Opin Immunol 2002; 14:709-17. 
23. Gohlke H, Illig T, Bahnweg M, et al. 
Association of the interleukin 1 receptor antagonist gene 
with asthma. Am J Respir Crit Care Med 2004; 169:1217-
23. 
24. Joki-Erkkila VP, Karjalainen J, 
Hulkkonen J, et al. Allergic rhinitis and 
polymorphisms of the interleukin 1 gene complex. Ann 
Allergy Asthma Immunol 2003; 9:275-9. 
25. Van Oosterhout AJM, Deurloo DT, 
Groot PC. Cytotoxic T lymphocyte antigen 4 
polymorphisms and allergic asthma. Clin Exp Allergy 
2004; 34:4-8 . 
26. Yang KD, Liu C-A, Chang J-C, et al. 
Polymorphism of the immune-braking gene CTLA-4 
(+49) involved in gender discrepancy of serum total IgE 
levels and allergic diseases. Clin Exp Allergy 2004; 34:32-
7 . 
27. Bourgain C, Hoffjan S, Nicolae R, et al. 
Novel case-control test in a founder population identifies 
P-selectin as an atopy-susceptibility locus. Am J Hum 
Genet 2003; 73:612-26. 
28. Heinzmann A, Jerkic SP, Ganter K, et al. 
Association study of the IL13 variant Arg110Gln in atopic 
diseases and juvenile idiopathic arthritis. J Allergy Clin 
Immunol 2003; 112:735-9. 
29. Blumenthal JB, Blumenthal MN. Genetics of 
asthma. Med Clin North Am 2002; 86:937-50 . 
30. Moffatt MF, Faux JA, Lester S, et al. 
Atopy, respiratory function and HLA-DR in Aboriginal 
Australians. Hum Mol Genet 2003; 12:625-30. 
31. Wang TN, Chen WY, Wang TH, et al. Gene-
gene synergistic effect on atopic asthma: tumour necrosis 
factor-alpha-308 and lymphotoxin-alpha-NcoI in Taiwan's 
children. Clin Exp Allergy 2004; 34:184-8 . 
32. Di Somma C, Charron D, Deichmann K, et 
al. Atopic asthma and TNF-308 alleles: linkage 
disequilibrium and association analyses. Hum Immunol 
2003; 64:359-65. 
33. Nagarkatti R, B-Rao C, Vijayan V, et al. 
Signal transducer and activator of transcription 6 
haplotypes and asthma in the Indian population. Am J 
Respir Cell Mol Biol 2004; 31:317-21.  
34. Shao C, Suzuki Y, Kamada F, et al. Linkage 
and association of childhood asthma with the chromosome 
12 genes. J Hum Genet 2004; 49:115-22.  
35. Tamura K, Suzuki M, Arakawa H, et al. 
Linkage and association studies of STAT6 gene 
polymorphisms and allergic diseases. Int Arch Allergy 
Immunol 2003; 131:33-8 . 
36. Gao PS, Mao XQ, Roberts MH, et al. 
Variants of STAT6 (signal transducer and activator of 
transcription 6) in atopic asthma. J Med Genet 2000; 
37:380-2. 
37. Holla LI, Schuller M, Buckova D, Vacha 
J. Neuronal nitric oxide synthase gene polymorphism and 
IgE-mediated allergy in the Central European population. 
Allergy 2004; 59:548-52. 
38. Shin HD, Park BL, Kim LH, et al. Association 
of tumor necrosis factor polymorphisms with asthma and 
serum total IgE. Hum Mol Genet 2004; 13:397-403. 
39. He JQ, Ruan J, Chan-Yeung M, et al. 
Polymorphisms of the GM-CSF genes and the 
development of atopic disease in at-risk children. Chest 
2003; 123:438S. 
40. Khoo SK, Hayden CM, Roberts M, et al. 
Associations of the IL12B promoter polymorphism in 
longitudinal data from asthmatic patients 7 to 42 years of 
age. J Allergy Clin Immunol 2004; 113:475-81. 
41. Lyon H, Lange C, Lake S, et al. IL10 gene 
polymorphisms are associated with asthma phenotypes in 
children. Genet Epidemiol 2004; 26:155-65. 
42. Wechsler ME, Israel E. How pharmacogenetics 




43. Hines RN, McCarver DG. Pharmacogenetics and 
the future of drug therapy. Pediatr Clin North Am 
2006;53(4):591-619. 
44. Fenech A, Hall IP. Pharmacogenetics of asthma. Br 
J Clin Pharm 2002;53(1):3-15 
45. Israel E, Drazen JM,Liggett SB, et al. 
Effects of polymorphism of the beta (2)-adrenergic 
receptors on response to regular use of albuterol in asthma. 
Int Arch All Immunol 2001:124(1-3):183-6. 
46. Kalayci O, Birben E, Sackesen C, et al. 
ALOX5 promoter genotype, asthma severity and LTC4 



























47. Mastalerz L, Nizankowska E, Sanak M, et 
al. Clinical and genetic features underlying the response 
of patients with bronchial asthma to the treatment with a 
leukotriene receptor antagonist. Eur J Clin Invest 
2002;32(12):949-55. 
48. Adcock IM, Lane SJ. Corticosteroid-insensitive 
asthma: molecular mechanisms. J Endocrinol 
2003;178(3):347-55 
49. Wiess ST, Lake SL, Silverman ES, et al. 
Asthma steroid pharmacogenetics: a study strategy to 
identify replicated treatment responses. Proc Am Thor Soc 
2004;1(4):364-7. 
50. Howard TD, Meyers DA, Bleecker ER. 
Mapping susceptibility genes for asthma and allergy .J 
Allergy Clin Immunol 2000 Feb; 105(2 Pt 2):S477-81. 
 
 
 
 
